File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Mycophenolate mofetil in the treatment of lupus nephritis: An appraisal of recent data

TitleMycophenolate mofetil in the treatment of lupus nephritis: An appraisal of recent data
Authors
KeywordsCyclophosphamide
Lupus Nephritis
Mycophenolate Mofetil
Issue Date2006
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APL
Citation
Aplar Journal Of Rheumatology, 2006, v. 9 n. 4, p. 403-407 How to Cite?
AbstractAfter nearly two decades of relative requiescence, a plethora of new drugs or biologic agents are currently being studied for their therapeutic potential in lupus nephritis. While corticosteroid remains an indispensable component in induction treatment for severe proliferative lupus nephritis, the advent of mycophenolate mofetil (MMF) offers an alternative to cyclophosphamide (CTX), thereby reducing the occurrence of treatment-related adverse effects, especially in patients requiring multiple courses of therapy for flares. Data on the high treatment efficacy and favourable tolerability of MMF were first reported in Chinese patients with diffuse proliferative lupus nephritis. The improved safety profile of MMF was subsequently confirmed in patients of Caucasian, Hispanic, or African origin, in whom comparable or even better treatment efficacy compared with CTX was observed. However, the response rates differed between these studies. This review aims to provide a succinct update on the reported experience that compared MMF with other immunosuppressive agents in the treatment of lupus nephritis. Considering potential ethnic differences in the disease course and/or treatment response, it remains to be examined whether the favourable long-term clinical outcomes observed in Chinese patients with corticosteroid and MMF as continuous treatment from induction to maintenance could be reproduced in patients of other ethnic origins. In addition, the relative merit and cost-effectiveness of MMF against alternative maintenance immunosuppressive agents in the prevention of disease flares deserve further investigation. © 2006 Asia Pacific League of Associations for Rheumatology.
Persistent Identifierhttp://hdl.handle.net/10722/163042
ISSN
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_US
dc.date.accessioned2012-09-05T05:26:54Z-
dc.date.available2012-09-05T05:26:54Z-
dc.date.issued2006en_US
dc.identifier.citationAplar Journal Of Rheumatology, 2006, v. 9 n. 4, p. 403-407en_US
dc.identifier.issn0219-0494en_US
dc.identifier.urihttp://hdl.handle.net/10722/163042-
dc.description.abstractAfter nearly two decades of relative requiescence, a plethora of new drugs or biologic agents are currently being studied for their therapeutic potential in lupus nephritis. While corticosteroid remains an indispensable component in induction treatment for severe proliferative lupus nephritis, the advent of mycophenolate mofetil (MMF) offers an alternative to cyclophosphamide (CTX), thereby reducing the occurrence of treatment-related adverse effects, especially in patients requiring multiple courses of therapy for flares. Data on the high treatment efficacy and favourable tolerability of MMF were first reported in Chinese patients with diffuse proliferative lupus nephritis. The improved safety profile of MMF was subsequently confirmed in patients of Caucasian, Hispanic, or African origin, in whom comparable or even better treatment efficacy compared with CTX was observed. However, the response rates differed between these studies. This review aims to provide a succinct update on the reported experience that compared MMF with other immunosuppressive agents in the treatment of lupus nephritis. Considering potential ethnic differences in the disease course and/or treatment response, it remains to be examined whether the favourable long-term clinical outcomes observed in Chinese patients with corticosteroid and MMF as continuous treatment from induction to maintenance could be reproduced in patients of other ethnic origins. In addition, the relative merit and cost-effectiveness of MMF against alternative maintenance immunosuppressive agents in the prevention of disease flares deserve further investigation. © 2006 Asia Pacific League of Associations for Rheumatology.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APLen_US
dc.relation.ispartofAPLAR Journal of Rheumatologyen_US
dc.subjectCyclophosphamideen_US
dc.subjectLupus Nephritisen_US
dc.subjectMycophenolate Mofetilen_US
dc.titleMycophenolate mofetil in the treatment of lupus nephritis: An appraisal of recent dataen_US
dc.typeArticleen_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1479-8077.2006.00232.xen_US
dc.identifier.scopuseid_2-s2.0-33750984190en_US
dc.identifier.hkuros148524-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33750984190&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume9en_US
dc.identifier.issue4en_US
dc.identifier.spage403en_US
dc.identifier.epage407en_US
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats